Picture BIO Deutschland EBDC 2016 Frankfurt 600x60px
Document › Details

Orexo AB. (3/6/12). "Press Release: Orexo AB Focuses Its Business and Reduces Costs". Uppsala.

Organisation Organisation Orexo AB (OMX Nordic List, Mid Cap: ORX)
  Group Orexo (Group)
Products Product OX219
  Product 2 OX51
Person Person Lundström, Anders (Orexo 201102– CEO before Biogen Idec + AstraZeneca + Janssen-Cilag + BMS)

Orexo AB is focusing its development activities to the three proprietary programs OX219, OX51 and OX27. The total requirement for resources will thereby be reduced with up to 35 full time employees.

The personnel reduction, which will have full effect in 2013, is expected to lower the costs by a total of SEK 30 million annually. Negotiations with trade union representatives will commence immediately. The reduction in personnel is expected to be completed during the second quarter of 2012.

"The focus of our business activities will now be fully in line with Orexo's strategy and we shall exclusively invest in further development and commercialization of our proprietary products. This means that we are directing all our resources towards our key later stage development programs," says CEO Anders Lundström.

The three programs, OX219, OX51 and OX27 are based on proprietary drug delivery technologies applied to well-known substances with licensed uses. This results in programs with significantly lower development risk, lower cost and shorter development time than traditional drug development programs. This approach was used to successfully develop Orexo's pain product Abstral® and the insomnia product Edluar™.

Orexo has today 110 employees, of which approximately 80 work in research and development.

For further information, please contact:
Anders Lundström, CEO
Phone: +46 70-667 22 66

About Orexo

Orexo develops and markets pharmaceuticals based on proprietary drug delivery technologies applied to well-known substances. The company's largest product is Abstral, a treatment of breakthrough cancer pain. Orexo's shares are listed on the Stockholm Stock Exchange and Danish Novo A/S and Swedish HealthCap are the largest shareholders. More information can be found at

Note: This is information that Orexo AB (publ) discloses pursuant to the Financial Instruments Trading Act and/or Securities Market Act. The information was provided for public release on March 6, 2012 at 11:00 CET. This press release has been prepared in both Swedish and English. In the event of any discrepancy in the content of the two versions, the Swedish version shall take precedence.

Record changed: 2015-08-10


Picture [LSUK] – The Business Web Portal 600x80px

More documents for Orexo (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group BIO Europe 2016 BEU Cologne November 120x180px Picture BIO Deutschland EBDC 2016 Frankfurt 120x240px Picture EBD Group BioPharm America 2016 BPA Boston September 120x80px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px